产品
编 号：F741753
分子式：C19H15N5
分子量：313.36
分子式：C19H15N5
分子量：313.36
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
结构图
CAS No: 2748337-86-0
产品详情
生物活性：
AZ12601011 is an orally active, selective TGFBR1 kinase inhibitor with an IC50 of 18 nM and a Kd of 2.9 nM. AZ12601011 inhibits phosphorylation of SMAD2 via selectively inhibiting ALK4, TGFBR1, and ALK7. AZ12601011 inhibits mammary tumor growth .
体内研究：
AZ12601011 (50mg/kg; oral gavage; twice daily; for 25 days) inhibits tumour growth and metastasis in vivo. Animal Model:Female BALB/c mice at greater than 18g with tumour
Dosage:50mg/kg
Administration:Oral gavage; twice daily; for 25 days
Result:Inhibited tumour growth and metastasis in vivo.
体外研究：
AZ12601011 (0.01-10 μM; for 20 minutes) completely inhibits Phosphorylation of SMAD2 . AZ12601011 (0.01 μM-10 μM) inhibits the activity of ALK4, ALK7 and TGFBR1 . AZ12601011 inhibits 4T1 cells growth in vitro (IC50=0.4μM) .
AZ12601011 is an orally active, selective TGFBR1 kinase inhibitor with an IC50 of 18 nM and a Kd of 2.9 nM. AZ12601011 inhibits phosphorylation of SMAD2 via selectively inhibiting ALK4, TGFBR1, and ALK7. AZ12601011 inhibits mammary tumor growth .
体内研究：
AZ12601011 (50mg/kg; oral gavage; twice daily; for 25 days) inhibits tumour growth and metastasis in vivo. Animal Model:Female BALB/c mice at greater than 18g with tumour
Dosage:50mg/kg
Administration:Oral gavage; twice daily; for 25 days
Result:Inhibited tumour growth and metastasis in vivo.
体外研究：
AZ12601011 (0.01-10 μM; for 20 minutes) completely inhibits Phosphorylation of SMAD2 . AZ12601011 (0.01 μM-10 μM) inhibits the activity of ALK4, ALK7 and TGFBR1 . AZ12601011 inhibits 4T1 cells growth in vitro (IC50=0.4μM) .
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备